Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

British American Tobacco H1 reported revenues, adjusted operating profits fall

(Sharecast News) - British American Tobacco reported a dip in H1 reported revenues and adjusted operating profits on Thursday, as currency pressures and reduced cigarette volumes weighed on its overall performance. Revenue fell 1.7% on a reported basis to £13.47bn for the six months ended 30 June, down from £13.71bn a year earlier. On a constant currency basis, however, revenue rose 2.6%, reflecting growth in its new categories segment and pricing across combustibles.

The FTSE 100-listed tobacco giant said adjusted operating profits slipped 4.2% to £5.89bn, while diluted earnings per share declined 5.7% to 163.8p, citing adverse FX movements and continued investment in its transformation strategy as key factors.

New categories revenue climbed 10.4% on a constant currency basis, driven by strong growth in vapour and modern oral products, and BAT said it now expects the segment to break even by 2025, a year ahead of schedule, while cigarette volumes dropped 9.1% globally, with notable declines in the US and South Asia, as consumer pressures and regulatory changes continued to impact demand.

BAT maintained its interim dividend at 235.52p per share and reaffirmed FY guidance for low-single-digit organic revenue growth and mid-single-digit adjusted operating profit growth at constant exchange rates.

"Our H1 performance is slightly ahead of expectations. 2025 is a deployment year and we are firmly on track to deliver our FY guidance," said chief executive Tadeu Marroco. "I am confident that the investments we have made and actions we are taking, will drive a return to our mid-term algorithm in 2026."

As of 0840 BST, BAT shares were up 1.53% at 4,050p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.